XORTX Therapeutics Inc.
XRTXNASDAQHealthcareBiotechnology
Previous close
$2.04
+$0.02 · +0.99%
XRTX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
28
Expensive
Momentum
25
Weakening
Sentiment
58
Mixed
Risk resilience
49
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteXORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CA
- CEO
- Allen Warren Davidoff
- Listed since
- Sep 23, 2021
- Employees
- 2
Market position
Day range
Current $2.04
52-week range
Current $2.04
- Open
- $2.0326
- Previous close
- $2.02
- Volume
- 1.69K
- 0.07× average
- Average volume
- 22.8K
- Average daily volume
- Market cap
- 568.12K USD
- Beta
- 0.08
- Market reference 1
- 50-day average
- $2.0971
- -2.72% below average
- 200-day average
- $2.4268
- -15.94% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -0.29×
- P/B (TTM)
- 0.61×
- P/S (TTM)
- 0×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
Financial health
- Debt / equity
- 0×
- Altman Z-score
- -6.99
- Piotroski F-score
- 1 of 9
Earnings
- EPS beat rate
- 67%
- 6 beats, 3 misses, 0 met estimates
- Average EPS surprise
- -21.28%
- 9 comparable reports
- Latest EPS result
- -1.05
EPS: actual versus estimate
Recent quarterly results
Corporate actions
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jan 31, 2014 | $0.0001Quarterly | Feb 4, 2014 | Feb 17, 2014 |
Dividend | Oct 15, 2013 | $0.0001Quarterly | Oct 17, 2013 | Nov 1, 2013 |
Dividend | Jul 11, 2013 | $0.0001Quarterly | Jul 15, 2013 | Jul 30, 2013 |
Dividend | Apr 16, 2013 | $0.0001Quarterly | Apr 18, 2013 | May 2, 2013 |
Dividend | Dec 24, 2012 | $0.0001Quarterly | Dec 27, 2012 | Dec 31, 2012 |
Dividend | Oct 12, 2012 | $0.0001Quarterly | — | Oct 30, 2012 |
Ex-dividend Jan 31, 2014
$0.0001
Quarterly
Record Feb 4, 2014 · Payment Feb 17, 2014
Ex-dividend Oct 15, 2013
$0.0001
Quarterly
Record Oct 17, 2013 · Payment Nov 1, 2013
Ex-dividend Jul 11, 2013
$0.0001
Quarterly
Record Jul 15, 2013 · Payment Jul 30, 2013
Ex-dividend Apr 16, 2013
$0.0001
Quarterly
Record Apr 18, 2013 · Payment May 2, 2013
Ex-dividend Dec 24, 2012
$0.0001
Quarterly
Record Dec 27, 2012 · Payment Dec 31, 2012
Ex-dividend Oct 12, 2012
$0.0001
Quarterly
Payment Oct 30, 2012
XRTX peers
Continue in GoAI
Research XRTXresearch.disclaimer